Concepts (671)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medulloblastoma | 42 | 2022 | 682 | 3.900 |
Why?
|
Cerebellar Neoplasms | 33 | 2022 | 590 | 3.230 |
Why?
|
Cranial Irradiation | 29 | 2022 | 395 | 2.360 |
Why?
|
Brain Neoplasms | 63 | 2024 | 9198 | 1.550 |
Why?
|
Ependymoma | 14 | 2023 | 328 | 1.500 |
Why?
|
Radiotherapy, Conformal | 11 | 2014 | 549 | 1.110 |
Why?
|
Hodgkin Disease | 36 | 2012 | 1386 | 1.050 |
Why?
|
Craniopharyngioma | 11 | 2021 | 279 | 0.990 |
Why?
|
Photons | 9 | 2015 | 595 | 0.970 |
Why?
|
Pituitary Neoplasms | 12 | 2021 | 1325 | 0.940 |
Why?
|
Radiotherapy Dosage | 51 | 2024 | 2922 | 0.900 |
Why?
|
Neoplasms, Second Primary | 18 | 2014 | 1060 | 0.850 |
Why?
|
Astrocytoma | 13 | 2005 | 780 | 0.840 |
Why?
|
Radiation Injuries | 18 | 2021 | 1204 | 0.820 |
Why?
|
Spinal Cord Neoplasms | 6 | 2023 | 263 | 0.750 |
Why?
|
Child, Preschool | 147 | 2024 | 42650 | 0.740 |
Why?
|
Rhabdomyosarcoma | 10 | 2014 | 358 | 0.700 |
Why?
|
Neoplasms, Radiation-Induced | 14 | 2013 | 555 | 0.680 |
Why?
|
Child | 180 | 2024 | 80891 | 0.680 |
Why?
|
Germinoma | 8 | 2021 | 132 | 0.670 |
Why?
|
Radiotherapy | 21 | 2015 | 1509 | 0.630 |
Why?
|
Protons | 14 | 2024 | 1112 | 0.620 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 24 | 2004 | 1558 | 0.600 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 57 | 2021 | 11854 | 0.590 |
Why?
|
Radiosurgery | 17 | 2005 | 1346 | 0.590 |
Why?
|
Career Mobility | 3 | 2017 | 262 | 0.590 |
Why?
|
Neuroectodermal Tumors, Primitive | 8 | 2015 | 137 | 0.550 |
Why?
|
Central Nervous System Neoplasms | 7 | 2015 | 930 | 0.540 |
Why?
|
Adolescent | 161 | 2024 | 89184 | 0.530 |
Why?
|
Radiotherapy, Intensity-Modulated | 7 | 2022 | 812 | 0.530 |
Why?
|
Cranial Nerve Neoplasms | 5 | 2006 | 134 | 0.520 |
Why?
|
Combined Modality Therapy | 65 | 2022 | 8562 | 0.480 |
Why?
|
Optic Nerve Glioma | 2 | 2006 | 32 | 0.480 |
Why?
|
Retinoblastoma | 8 | 2014 | 321 | 0.470 |
Why?
|
Faculty, Medical | 6 | 2021 | 1218 | 0.450 |
Why?
|
Infratentorial Neoplasms | 6 | 2017 | 99 | 0.420 |
Why?
|
Disease-Free Survival | 29 | 2022 | 6856 | 0.410 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 6 | 2021 | 494 | 0.400 |
Why?
|
Bone Marrow Transplantation | 18 | 2007 | 2709 | 0.390 |
Why?
|
Radiotherapy, High-Energy | 6 | 2004 | 228 | 0.390 |
Why?
|
Glioma | 11 | 2019 | 3526 | 0.390 |
Why?
|
Vincristine | 26 | 2015 | 1040 | 0.380 |
Why?
|
Supratentorial Neoplasms | 5 | 2015 | 159 | 0.360 |
Why?
|
Methotrexate | 18 | 2012 | 1722 | 0.360 |
Why?
|
Neoplasm Recurrence, Local | 26 | 2023 | 9433 | 0.360 |
Why?
|
Infant | 74 | 2021 | 36510 | 0.360 |
Why?
|
Radiodermatitis | 2 | 2011 | 61 | 0.340 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 15 | 2022 | 1680 | 0.330 |
Why?
|
Whole-Body Irradiation | 11 | 1998 | 435 | 0.320 |
Why?
|
Bone Neoplasms | 12 | 2014 | 2565 | 0.320 |
Why?
|
Male | 191 | 2024 | 364902 | 0.310 |
Why?
|
Physicians, Women | 5 | 2008 | 520 | 0.310 |
Why?
|
Optic Chiasm | 5 | 2014 | 91 | 0.310 |
Why?
|
Neoplasm Staging | 25 | 2016 | 11254 | 0.290 |
Why?
|
Humans | 258 | 2024 | 768393 | 0.290 |
Why?
|
Female | 186 | 2024 | 397089 | 0.290 |
Why?
|
Central Nervous System Cysts | 1 | 2007 | 56 | 0.290 |
Why?
|
Lens, Crystalline | 2 | 2007 | 387 | 0.280 |
Why?
|
Etoposide | 7 | 2015 | 639 | 0.280 |
Why?
|
Follow-Up Studies | 52 | 2021 | 39407 | 0.270 |
Why?
|
Orbital Neoplasms | 3 | 2005 | 223 | 0.270 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2012 | 349 | 0.270 |
Why?
|
Spinal Neoplasms | 4 | 2014 | 716 | 0.260 |
Why?
|
Leadership | 3 | 2018 | 1395 | 0.260 |
Why?
|
Prejudice | 2 | 2007 | 574 | 0.250 |
Why?
|
Carboplatin | 3 | 2021 | 799 | 0.250 |
Why?
|
Survival Rate | 36 | 2015 | 12870 | 0.240 |
Why?
|
Prednisolone | 5 | 1994 | 327 | 0.240 |
Why?
|
Brain Stem | 4 | 2022 | 862 | 0.240 |
Why?
|
Parental Leave | 2 | 2021 | 93 | 0.240 |
Why?
|
Eye Neoplasms | 4 | 2003 | 306 | 0.240 |
Why?
|
Preceptorship | 1 | 2004 | 57 | 0.230 |
Why?
|
Radiation Oncology | 2 | 2022 | 573 | 0.230 |
Why?
|
Pituitary Irradiation | 2 | 1994 | 14 | 0.230 |
Why?
|
Academic Medical Centers | 3 | 2017 | 2783 | 0.230 |
Why?
|
Organs at Risk | 6 | 2022 | 368 | 0.230 |
Why?
|
Radiation Injuries, Experimental | 4 | 1994 | 88 | 0.220 |
Why?
|
Cyclophosphamide | 18 | 2015 | 2226 | 0.220 |
Why?
|
Cisplatin | 8 | 2015 | 1661 | 0.220 |
Why?
|
Etanidazole | 1 | 2003 | 22 | 0.220 |
Why?
|
Cysts | 1 | 2009 | 685 | 0.220 |
Why?
|
Radiotherapy, Adjuvant | 11 | 2021 | 1794 | 0.220 |
Why?
|
Treatment Outcome | 53 | 2021 | 65379 | 0.220 |
Why?
|
Young Adult | 33 | 2024 | 60049 | 0.210 |
Why?
|
Radiology Department, Hospital | 1 | 2006 | 409 | 0.210 |
Why?
|
Relative Biological Effectiveness | 7 | 2021 | 313 | 0.200 |
Why?
|
Stereotaxic Techniques | 5 | 1996 | 556 | 0.200 |
Why?
|
Retrospective Studies | 49 | 2023 | 81801 | 0.190 |
Why?
|
Alopecia | 4 | 2014 | 416 | 0.190 |
Why?
|
Adult | 96 | 2024 | 223640 | 0.190 |
Why?
|
Thoracic Neoplasms | 3 | 2014 | 269 | 0.190 |
Why?
|
Survival Analysis | 16 | 2016 | 10117 | 0.190 |
Why?
|
Fund Raising | 1 | 2021 | 49 | 0.190 |
Why?
|
Rhabdomyosarcoma, Embryonal | 3 | 2015 | 99 | 0.190 |
Why?
|
Olfaction Disorders | 1 | 2024 | 226 | 0.190 |
Why?
|
Dose-Response Relationship, Radiation | 12 | 2008 | 881 | 0.190 |
Why?
|
Cancer Care Facilities | 1 | 2004 | 424 | 0.180 |
Why?
|
Brain Stem Neoplasms | 1 | 2003 | 191 | 0.180 |
Why?
|
Health Care Rationing | 1 | 2004 | 435 | 0.180 |
Why?
|
Memory Disorders | 5 | 2018 | 1203 | 0.180 |
Why?
|
Cognition | 9 | 2021 | 7075 | 0.180 |
Why?
|
Intelligence | 5 | 2018 | 929 | 0.170 |
Why?
|
Growth Disorders | 3 | 2022 | 635 | 0.170 |
Why?
|
Organizational Policy | 2 | 2021 | 434 | 0.170 |
Why?
|
Diabetes Insipidus | 2 | 2016 | 144 | 0.170 |
Why?
|
Prognosis | 29 | 2016 | 30022 | 0.170 |
Why?
|
Age Factors | 15 | 2021 | 18471 | 0.170 |
Why?
|
Linear Energy Transfer | 3 | 2017 | 154 | 0.170 |
Why?
|
Doxorubicin | 19 | 2015 | 2229 | 0.160 |
Why?
|
Anti-Inflammatory Agents | 1 | 2009 | 1813 | 0.160 |
Why?
|
Mentors | 1 | 2004 | 672 | 0.160 |
Why?
|
Optic Nerve Neoplasms | 1 | 1999 | 45 | 0.160 |
Why?
|
Sex Factors | 12 | 2021 | 10654 | 0.160 |
Why?
|
Salaries and Fringe Benefits | 1 | 2021 | 262 | 0.160 |
Why?
|
Tectum Mesencephali | 1 | 1998 | 18 | 0.160 |
Why?
|
Lymphopenia | 1 | 2021 | 299 | 0.150 |
Why?
|
Confidence Intervals | 3 | 2017 | 2931 | 0.150 |
Why?
|
Spine | 2 | 2017 | 1141 | 0.150 |
Why?
|
Pituitary Gland | 2 | 2018 | 634 | 0.150 |
Why?
|
Medulla Oblongata | 1 | 1999 | 248 | 0.150 |
Why?
|
SEER Program | 2 | 2013 | 1474 | 0.150 |
Why?
|
Sarcoma | 6 | 2003 | 1807 | 0.150 |
Why?
|
Meningeal Neoplasms | 4 | 2015 | 1253 | 0.140 |
Why?
|
Wechsler Scales | 1 | 2018 | 258 | 0.140 |
Why?
|
Drug Administration Schedule | 9 | 2013 | 4859 | 0.140 |
Why?
|
Hypophysectomy | 2 | 1994 | 114 | 0.140 |
Why?
|
Pediatrics | 3 | 2018 | 3624 | 0.140 |
Why?
|
Neuropsychological Tests | 9 | 2018 | 7145 | 0.140 |
Why?
|
Scattering, Radiation | 2 | 2017 | 489 | 0.140 |
Why?
|
Neoplasms, Multiple Primary | 5 | 2014 | 594 | 0.140 |
Why?
|
Spinal Cord | 3 | 2021 | 1813 | 0.140 |
Why?
|
Mediastinal Neoplasms | 6 | 1997 | 403 | 0.130 |
Why?
|
Abortion, Induced | 1 | 2022 | 475 | 0.130 |
Why?
|
Gynecomastia | 1 | 2016 | 88 | 0.130 |
Why?
|
Soft Tissue Neoplasms | 3 | 1997 | 1167 | 0.130 |
Why?
|
Neurologic Examination | 3 | 1997 | 916 | 0.130 |
Why?
|
Magnetic Resonance Spectroscopy | 5 | 2015 | 3781 | 0.130 |
Why?
|
Neurofibromatosis 1 | 3 | 2007 | 561 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 11 | 2013 | 3553 | 0.130 |
Why?
|
Time Factors | 19 | 2021 | 40272 | 0.130 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 1997 | 171 | 0.120 |
Why?
|
Dactinomycin | 6 | 2006 | 305 | 0.120 |
Why?
|
Survivors | 9 | 2020 | 2382 | 0.120 |
Why?
|
Neoplasms | 6 | 2021 | 22385 | 0.120 |
Why?
|
Rhabdoid Tumor | 2 | 2017 | 211 | 0.120 |
Why?
|
Transplantation Conditioning | 4 | 2007 | 1600 | 0.120 |
Why?
|
Endocrine System | 1 | 2015 | 113 | 0.120 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2015 | 58 | 0.120 |
Why?
|
Teratoma | 3 | 2017 | 405 | 0.120 |
Why?
|
Magnetic Resonance Imaging | 24 | 2016 | 36849 | 0.120 |
Why?
|
Procarbazine | 9 | 2004 | 172 | 0.120 |
Why?
|
Central Nervous System Diseases | 2 | 1997 | 523 | 0.120 |
Why?
|
Mediastinum | 3 | 2004 | 272 | 0.120 |
Why?
|
Recurrence | 17 | 2023 | 8506 | 0.120 |
Why?
|
Prednisone | 13 | 2012 | 1567 | 0.110 |
Why?
|
Leukemia, Lymphoid | 4 | 1988 | 311 | 0.110 |
Why?
|
Radiology | 2 | 2007 | 2117 | 0.110 |
Why?
|
Leukemia, Experimental | 1 | 1994 | 225 | 0.110 |
Why?
|
Pituitary Gland, Posterior | 1 | 2013 | 42 | 0.110 |
Why?
|
Ploidies | 2 | 1994 | 287 | 0.110 |
Why?
|
Transplantation Chimera | 3 | 2007 | 594 | 0.110 |
Why?
|
Neuroblastoma | 4 | 1997 | 1266 | 0.110 |
Why?
|
Neoplasm Seeding | 1 | 1993 | 85 | 0.110 |
Why?
|
Vomiting | 4 | 2024 | 655 | 0.110 |
Why?
|
Hypothalamus | 1 | 2018 | 1004 | 0.110 |
Why?
|
Delayed Diagnosis | 2 | 2016 | 469 | 0.110 |
Why?
|
Nasal Cavity | 1 | 2015 | 311 | 0.100 |
Why?
|
Oligodendroglioma | 2 | 1993 | 278 | 0.100 |
Why?
|
Nose Neoplasms | 1 | 2015 | 250 | 0.100 |
Why?
|
Disease Progression | 11 | 2021 | 13646 | 0.100 |
Why?
|
Monte Carlo Method | 5 | 2017 | 1261 | 0.100 |
Why?
|
Nausea | 3 | 2024 | 682 | 0.100 |
Why?
|
Pelvic Neoplasms | 1 | 2014 | 250 | 0.100 |
Why?
|
Nervous System Diseases | 1 | 2003 | 1664 | 0.100 |
Why?
|
Retinal Neoplasms | 1 | 2014 | 151 | 0.100 |
Why?
|
Treatment Failure | 8 | 2015 | 2663 | 0.100 |
Why?
|
Pineal Gland | 1 | 2013 | 158 | 0.100 |
Why?
|
Skull | 2 | 1994 | 831 | 0.100 |
Why?
|
Neurosurgical Procedures | 1 | 2003 | 2097 | 0.100 |
Why?
|
Cohort Studies | 15 | 2022 | 41795 | 0.100 |
Why?
|
Brachytherapy | 3 | 1996 | 1226 | 0.090 |
Why?
|
Hippocampus | 3 | 2022 | 3784 | 0.090 |
Why?
|
Radiometry | 3 | 2018 | 817 | 0.090 |
Why?
|
Brain | 15 | 2016 | 27454 | 0.090 |
Why?
|
Dental Caries | 1 | 1995 | 429 | 0.090 |
Why?
|
Incidence | 13 | 2017 | 21544 | 0.090 |
Why?
|
Quality-Adjusted Life Years | 2 | 2015 | 1735 | 0.090 |
Why?
|
Prospective Studies | 18 | 2024 | 54920 | 0.090 |
Why?
|
Quality of Life | 7 | 2020 | 13503 | 0.090 |
Why?
|
Moyamoya Disease | 2 | 2021 | 274 | 0.090 |
Why?
|
Schools, Medical | 1 | 2017 | 881 | 0.090 |
Why?
|
Mechlorethamine | 7 | 1993 | 129 | 0.090 |
Why?
|
Nervous System | 1 | 1994 | 547 | 0.090 |
Why?
|
Postoperative Complications | 8 | 2003 | 15881 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 3 | 2016 | 6541 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 19 | 2009 | 20765 | 0.090 |
Why?
|
Hypogonadism | 1 | 2016 | 805 | 0.090 |
Why?
|
Periodicals as Topic | 3 | 2021 | 1469 | 0.090 |
Why?
|
Endocrine System Diseases | 3 | 2018 | 250 | 0.090 |
Why?
|
Hematologic Neoplasms | 4 | 2007 | 1905 | 0.090 |
Why?
|
Oral Health | 1 | 1995 | 493 | 0.080 |
Why?
|
Lung | 7 | 1995 | 10089 | 0.080 |
Why?
|
Behavior, Animal | 3 | 1994 | 1879 | 0.080 |
Why?
|
Nervous System Neoplasms | 1 | 1990 | 91 | 0.080 |
Why?
|
Remission Induction | 9 | 2005 | 2407 | 0.080 |
Why?
|
Cost Savings | 1 | 2015 | 915 | 0.080 |
Why?
|
Vinblastine | 5 | 2012 | 488 | 0.080 |
Why?
|
Ifosfamide | 3 | 2006 | 234 | 0.080 |
Why?
|
Cranial Nerve Injuries | 1 | 2009 | 28 | 0.080 |
Why?
|
Emollients | 1 | 2009 | 42 | 0.080 |
Why?
|
Thorax | 2 | 2004 | 559 | 0.080 |
Why?
|
Executive Function | 1 | 2017 | 1405 | 0.080 |
Why?
|
Antineoplastic Agents | 6 | 2013 | 13697 | 0.080 |
Why?
|
DNA, Neoplasm | 2 | 1997 | 1748 | 0.080 |
Why?
|
Analysis of Variance | 7 | 2018 | 6241 | 0.080 |
Why?
|
Cognition Disorders | 5 | 2009 | 3985 | 0.080 |
Why?
|
Fellowships and Scholarships | 1 | 2017 | 1133 | 0.080 |
Why?
|
Risk Assessment | 6 | 2017 | 24318 | 0.080 |
Why?
|
Pelvic Bones | 2 | 2010 | 274 | 0.080 |
Why?
|
United States | 13 | 2022 | 73150 | 0.070 |
Why?
|
Lymphoma, Non-Hodgkin | 5 | 2003 | 1376 | 0.070 |
Why?
|
Radiation Dosage | 5 | 2007 | 1974 | 0.070 |
Why?
|
Hospitals | 1 | 2021 | 3906 | 0.070 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3633 | 0.070 |
Why?
|
Head and Neck Neoplasms | 2 | 2014 | 2923 | 0.070 |
Why?
|
Cytogenetics | 1 | 2007 | 198 | 0.070 |
Why?
|
Adenoma | 2 | 1996 | 2163 | 0.070 |
Why?
|
Hypopituitarism | 1 | 2009 | 252 | 0.070 |
Why?
|
Injections, Spinal | 6 | 2005 | 318 | 0.070 |
Why?
|
Middle Aged | 44 | 2022 | 223491 | 0.070 |
Why?
|
Pleural Effusion | 2 | 1989 | 344 | 0.070 |
Why?
|
Radiation-Protective Agents | 1 | 1986 | 88 | 0.070 |
Why?
|
Chondrosarcoma | 1 | 2009 | 306 | 0.070 |
Why?
|
Brain Damage, Chronic | 3 | 1997 | 267 | 0.070 |
Why?
|
Women | 1 | 2008 | 226 | 0.070 |
Why?
|
Risk Factors | 22 | 2019 | 74962 | 0.060 |
Why?
|
Proportional Hazards Models | 5 | 2015 | 12558 | 0.060 |
Why?
|
Lymphocyte Transfusion | 2 | 2005 | 232 | 0.060 |
Why?
|
Health Services Accessibility | 2 | 2019 | 5512 | 0.060 |
Why?
|
Tumor Burden | 3 | 2021 | 1913 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 1999 | 3541 | 0.060 |
Why?
|
Acetylcysteine | 1 | 1986 | 262 | 0.060 |
Why?
|
Aspartic Acid | 2 | 2004 | 577 | |